Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Past 24 hours
Any time
Past hour
Past 7 days
Past 30 days
Most recent
Best match
26m
Wuxi Biologics Is a Global CRDMO With Near-Term Geopolitical Risks
Our fair value estimate for WuXi is HKD 24.60 per share. WuXi has been growing at a CAGR of 53.3% for the past eight years. Although its USD 20.5 billion total backlog revenue supports our growth ...
FiercePharma
19h
With BIOSECURE in limbo, should BeiGene or Legend sell itself in 2025? Analysts weigh in
When the BIOSECURE Act hit a setback and missed the chance of becoming law in 2024, the deceleration of the draft legislation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
CA fires death toll rises
California fires: How to help
Court allows report release
Singer Anita Bryant dies
'Pizzagate' gunman killed
1.2M-year-old ice core
La Nina finally arrives
Sues over ‘Rust' prosecution
Freed after brief detention
Judge scraps Title IX rules
Wycheck had CTE
Ski patrol strike ends
Peacock president to exit
Sworn in as NH governor
Economic growth forecast
Appeals her disqualification
Teen arrested with a gun
Presidential palace attack
Oscar nominations delayed
Must face defamation suit
Bill to sanction ICC OK'd
ACLU sues DeSantis
Crime leader pleads guilty
SCOTUS rejects Trump’s bid
Santos' sentencing delayed
Lebanon's new president
Clarifies Siri privacy stance
New Orleans hires Bratton
US settles w/ Johns Hopkins
Settles opioid lawsuit
Related topics
WuXi
United States
Merck & Co.
Republic of Ireland
Feedback